Drug intelligence / Profile preview

KFRX-04

Development stage: Preclinical
Lead developer: KeifeRx
Modality: Small Molecules
Administration: Oral

Overview

**KFRX-04** is a novel small molecule tyrosine kinase inhibitor (TKI) developed by KeifeRx, optimized for low-dose oral delivery with blood-brain barrier penetration. It acts as a dual inhibitor of **PIKFYVE** (phosphoinositide kinase, FYVE-type zinc finger containing) and **c-Kit** (stem cell growth factor receptor), promoting autophagy to clear toxic proteins and modulating mast cell activity to reduce inflammation. Primarily targeted for mast cell-related disorders, it shows promise in neurodegenerative conditions due to its central nervous system activity.[1][3][5][11]

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)PIKFYVE (Phosphoinositide kinase, FYVE-type zinc finger containing enzyme)

Beyond the preview

Go deeper on KFRX-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KFRX-04.

Explore the full profile